Viewing Study NCT04586803


Ignite Creation Date: 2025-12-24 @ 7:45 PM
Ignite Modification Date: 2025-12-28 @ 1:46 AM
Study NCT ID: NCT04586803
Status: UNKNOWN
Last Update Posted: 2020-10-14
First Post: 2020-09-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:

Study Overview

Official Title: Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, 3 Cycles, 6 Sequences)
Status: UNKNOWN
Status Verified Date: 2020-10
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of the study is to evaluate the relative bioavailability of three different prescription processes of SHR4640 tablets in healthy volunteers. The secondary objective of the study is to observe the safety of SHR4640 tablets in healthy subjects.
Detailed Description: Study Type: Interventional Enrollment: Number of Subjects: 24 Type: Anticipated

Allocation : Yes Intervention Model : Single center, randomized, open Intervention Model Description: 3 cycles, 6 sequences Masking: No Masking

Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: